NCT02306915View on ClinicalTrials.gov

PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

May 31, 2015

Conditions
PharmacokineticsPharmacodynamics
Interventions
DRUG

lipegfilgrastim

lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg

Trial Locations (1)

Unknown

Teva Investigational Site 34193, London

All Listed Sponsors
lead

Merckle GmbH

INDUSTRY

NCT02306915 - PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants | Biotech Hunter | Biotech Hunter